In this task, you're given a passage that represents a legal contract or clause between multiple parties, followed by a question that needs to be answered. Based on the paragraph, you must write the index where the answer starts. If multiple answers seem to exist, write the index of the answer that is the most plausible. If multiple indices must be used to answer the question, the output should be a common separated list of indices.

Ex Input:
EXHIBIT 10.3

Yield Maintenance Agreement

[LOGO UBS]

Date:               27 April 2006

To:                 Wells Fargo Bank, N.A., not individually, but solely as                     Master Servicer on behalf of Wells Fargo Mortgage Backed                     Securities 2006-6 Trust (Counterparty)

Attention:          Swaps Administration

From:               UBS AG, London Branch (UBS AG)

Subject:            Interest Rate Cap Transaction                     UBS AG Ref: 37346733

Dear Sirs

The purpose of this communication is to confirm the terms and conditions of the Transaction entered into between us on the Trade Date specified below. This Confirmation constitutes a Confirmation as referred to in the Master Agreement or Agreement specified below.

The definitions contained in the 2000 ISDA Definitions as published by the International Swaps and Derivatives Association, Inc., are incorporated into this Confirmation. In the event of any inconsistency between any of the definitions listed above and this Confirmation, this Confirmation will govern.

If you and we are parties to a master agreement that governs transactions of this type (whether in the form of the 1992 ISDA Master Agreement (Multicurrency-Cross Border)(the ISDA Form) or any other form (a Master Agreement), then this Confirmation will supplement, form a part of, and be subject to that Master Agreement. If you and we are not parties to such a Master Agreement, then you and we agree to use all reasonable efforts promptly to negotiate, execute and deliver an agreement in the form of the ISDA Form, with such modifications as you and we will in good faith agree. Upon the execution by you and us of such an agreement, this Confirmation will supplement, form a part of and be subject to and governed by that agreement, except as expressly modified below. Until we execute and deliver that agreement, this Confirmation, together with all other documents referring to the ISDA Form (each a Confirmation) confirming transactions (each a Transaction) entered into between us (notwithstanding anything to the contrary in a confirmation), shall supplement, form a part of, and be subject to an agreement in the form of the ISDA Form as if we had executed an agreement in such form (but without any Schedule except for the election of the laws of New York as the Governing Law and U.S. Dollars as the Termination Currency) on the Trade Date of the first Transaction between us (hereinafter the Agreement). In the event of any inconsistency between the provisions of any such Agreement and this Confirmation, this Confirmation will prevail for the purposes of this Transaction.

The terms of the particular Swap Transaction to which this Confirmation relates are as follows:

General Terms

Trade Date:                       27 April 2006

Effective Date                    01 April 2006

Termination Date:                  1 April 2009

Calculation Amount:               The lesser of (a) USD 20,000,000.00 and (b)                                   the aggregate Principal Balance (as defined                                   in the Pooling and Servicing Agreement) of the                                   Class I-A-22 Certificates as of the last day                                   of the relevant Calculation Period.

Seller of the Cap:                UBS AG

Buyer of the Cap:                 Counterparty

Calculation Agent:                UBS AG

Business Days:                    New York

Broker:                           None

Fixed Amounts

Fixed Rate Payer:                Counterparty

Fixed Amount:                    USD[              ]

Fixed Rate Payer Payment Date:   27 April 2006

Business Day Convention:         Not Applicable

Floating Amounts





Floating Rate Payer:             UBS AG

Cap Rate:                        5.0 percent per annum

Floating Amount:                 To be determined in accordance with the                                  following formula:                                  Greater of                                  (1)Calculation  Amount *  Floating  Rate Day                                  Count Fraction * (Floating Rate Option - Cap                                  Rate) and (2) 0

Floating Rate Option:            USD-LIBOR-BBA

Designated Maturity:             One Month

Spread:                          None

Floating Rate Day Count          30/360 Fraction:

Floating Rate Payer Period       01 January,  01 February,  01 March,  01 April, End  Dates:                      01 May, 01 June, 01 July, 01 August, 01                                  September,  01 October, 01 November and 01                                  December, in each year, from and including 01                                  May 2006, up to and including the Termination                                  Date, subject to adjustment in accordance with                                  the Business DayConvention specified                                  immediately below, and thereshall be No                                  Adjustment to the Period End Dates.

Floating Rate Payer Payment      Delayed  Payment shall be applicable.  The Dates:                           FloatingRate  Payer  Payment  Dates  shall be                                  two  Business Days prior to 25 January, 25                                  February, 25 March, 25 April, 25 May, 25 June,                                  25 July, 25 August, 25 September, 25 October,                                  25 November and 25 December, in each year, from                                  and including 25 May 2006, up to and including                                  25 April 2009, notwithstanding the specified &bbsp;                                Termination Date, subject to adjustment in                                  accordance with the Business Day Convention                                  specified immediately below.

Reset Dates:                     First day of each Calculation Period.

Business Day Convention:         Modified Following

Additional Provisions

(i)     Specified Transaction shall have the meaning specified in Section 14         of the ISDA Form.

(ii)    The Breach of Agreement provisions of Section 5(a)(ii) of the ISDA         Form will be applicable to UBS AG and inapplicable to the Counterparty.

(iii)   The Credit Support Default provisions of Section 5(a)(iii) of the ISDA         Form will be inapplicable to UBS AG and the Counterparty.

(iv)    The Misrepresentation provisions of Section 5(a)(iv) of the ISDA Form         will be inapplicable to UBS AG and the Counterparty.

(v)     The Default Under Specified Transaction provisions of Section 5(a)(v)         of the ISDA Form will be inapplicable to UBS AG and the Counterparty.

(vi)    The Cross Default provisions of Section 5(a)(vi) of the ISDA Form will         be inapplicable to UBS AG and the Counterparty.

(vii)   The Credit Event Upon Merger provisions of Section 5(b)(iv) of the         ISDA Form will be inapplicable to UBS AG and the Counterparty.

(viii)  The Automatic Early Termination provision of Section 6(a) of the ISDA         Form will be inapplicable to UBS AG and the Counterparty.

(ix)    Severability. If any term, provision, covenant, or condition of this         Agreement, or the application thereof to any party or circumstance,         shall be held to be invalid or unenforceable (in whole or in part) for         any reason, the remaining terms, provisions, covenants, and conditions         hereof shall continue in full force and effect as if this Agreement had         been executed with the invalid or unenforceable portion eliminated, so         long as this Agreement as so modified continues to express, without         material change, the original intentions of the parties as to the         subject matter of this Agreement and the deletion of such portion of         this Agreement will not substantially impair the respective benefits or         expectations of the parties; provided, however, that this severability         provision will not be applicable if any provision of Section 2, 5, 6 or         13 (or any definition or provision in Section 14 to the extent it         relates to, or is used in or in connection with, such section) is held         to be invalid or unenforceable, provided, further, that the parties         agree to first use reasonable efforts to amend the affected provisions         of Section 2, 5, 6 or 13 (or any definition or provision in Section 14         to the extent it relates to, or is used in or in connection with, such         section) so as to preserve the original intention of the parties.

The parties shall endeavor to engage in good faith negotiations to         replace any invalid or unenforceable term, provision, covenant or         condition with a valid or enforceable term, provision, covenant or         condition, the economic effect of which comes as close as possible to





that of the invalid or unenforceable term, provision, covenant or         condition.

(x)     Consent to Recording. Each party hereto consents to the monitoring or         recording, at any time and from time to time, by the other party of any         and all communications between officers or employees of the parties,         waives any further notice of such monitoring or recording, and agrees to         notify its officers and employees of such monitoring or recording.

(xi)    Waiver of Jury Trial. EACH PARTY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO         TRIAL BY JURY IN ANY LEGAL PROCEEDING IN CONNECTION WITH THIS AGREEMENT,         ANY CREDIT SUPPORT DOCUMENT TO WHICH IT IS A PARTY, OR ANY TRANSACTION.         EACH PARTY ALSO ACKNOWLEDGES THAT THIS WAIVER IS A MATERIAL INDUCEMENT         TO THE OTHER PARTY'S ENTERING INTO THIS AGREEMENT.

(xii) Fully Paid Transaction. Notwithstanding the terms of Sections 5 and             6 of the Agreement, if Counterparty has satisfied all of its payment             obligations under Section 2(a)(i) of the Agreement with respect to             this Transaction, and unless UBS AG is required to return (whether             pursuant to an order of a court with due authority to cause UBS AG             to be required to return any such payment to Counterparty (or any             duly authorized representative thereof) or whether otherwise             pursuant to appropriate proceedings to return to Counterparty (or             any duly authorized representative thereof)) or UBS AG otherwise             returns to Counterparty (or any duly authorized representative             thereof) upon demand of Counterparty (or any duly authorized             representative thereof) any portion of such payment, then: (a) the             occurrence of an event described in Section 5(a) of the Agreement             with respect to Counterparty shall not constitute an Event of             Default or Potential Event of Default with respect to Counterparty             as the Defaulting Party in respect of this Transaction and (b) UBS             AG shall be entitled to designate an Early Termination Date pursuant             to Section 6 of the Agreement in respect of this Transaction only as             a result of a Termination Event set forth in either Section 5(b)(i)             or Section 5(b)(ii) of the Agreement with respect to UBS AG as the             Affected Party or Section 5(b)(iii) of the Agreement with respect to             UBS AG as the Burdened Party. For purposes of the Transaction to             which this Confirmation relates, Counterparty's only obligation             under Section 2(a)(i) of the Agreement is to pay the Fixed Amount on             the Fixed Rate Payer Payment Date, each as defined in this             Confirmation.

(xiii)  Governing Law. The parties to this Agreement hereby agree that the law         of the State of New York shall govern their rights and duties in whole         without regard to the conflict of law provisions thereof (other than New         York General Obligations Law Sections 5-1401 and 5-1402).

(xiv)   Non-Recourse. Notwithstanding any provision herein or in the ISDA Form         to the contrary, the obligations of Counterparty hereunder are limited         recourse obligations of Counterparty, payable solely from the Trust         Estate (as defined in the Pooling and Servicing Agreement) and the         proceeds thereof to satisfy Counterparty's obligations hereunder. In the         event that the Trust Estate and proceeds thereof should be insufficient         to satisfy all claims outstanding and following the realization of the         Trust Estate and the distribution of the proceeds thereof in accordance         with the Pooling and Servicing Agreement, any claims against or         obligations of Counterparty under the ISDA Form or any other         confirmation thereunder, still outstanding shall be extinguished and         thereafter not revive.

(xv)    Set-Off. Notwithstanding any provision of this Agreement or any other         existing or future agreement, each party irrevocably waives any and all         rights it may have to set off, net, recoup or otherwise withhold or         suspend or condition payment or performance of any obligation between it         and the other party hereunder against any obligation between it and the         other party under any other agreements. The provisions for Set-off set         forth in Section 6(e) of the Agreement shall not apply for purposes of         this Transaction; provided, however, that upon the designation of any         Early Termination Date, in addition to, and not in limitation of any         other right or remedy under applicable law, UBS AG may, by notice to         Counterparty require Counterparty to set off any sum or obligation that         UBS AG owed to Counterparty against any collateral currently held by         Counterparty that UBS AG has posted to Counterparty, and Counterparty         shall effect such setoff promptly, if and to the extent permitted to do         so under applicable law, provided that Counterparty's exercise of this         setoff is not stayed or otherwise delayed by order of any court,         regulatory authority or other governmental agency or any receiver other         person appointed in respect of UBS AG or any of its property.

(xvi)   Proceedings. UBS AG covenants and agrees that it will not institute         against or join any other person in instituting against the Counterparty         any bankruptcy, reorganization, arrangement, insolvency, winding up or         liquidation proceedings, or other proceedings under any United States         federal or state law, or other bankruptcy, insolvency, liquidation, or         similar law, in connection with any obligations relating to this         Transaction or otherwise prior to the date that is one year and one day         or, if longer, the applicable preference period after all the         Certificates (as defined below) have been paid in full; provided, that         this paragraph shall not restrict or prohibit UBS AG, after the filing         of any proceeding filed independently of UBS AG, from joining any other         person, including without limitation the Master Servicer, in any         bankruptcy, reorganization, arrangement, insolvency, moratorium,         liquidation or other analogous proceedings relating to Counterparty         under any bankruptcy or similar law.





(xvii)  The ISDA Form is hereby amended as follows: for the purposes of this         Transaction, the word third shall be replaced by he word first in         the third line of Section 5(a)(i) of the ISDA Form; provided, however,         that notwithstanding the foregoing, an Event of Default shall not occur         under either if, as demonstrated to the reasonable satisfaction of the         other party, (a) the failure to pay or deliver is caused by an error or         omission of an administrative or operational nature; and (b) funds or         the relevant instrument were available to such party to enable it to         make the relevant payment or delivery when due; and (c) such relevant         payment is made within the earlier of (a) three Business Days following         receipt of written notice from an the other party of such failure to pay         or (b) 12:00 p.m. Eastern Standard Time on the Distribution Date (as         defined in the Pooling and Servicing Agreement) immediately following         the failure to pay.

(xviii) Multibranch Party. For the purpose of Section 10(c) of the Agreement:

(i)     UBS AG is a Multibranch Party and may act through its branches                 in any of the following territories or countries: England and                 Wales, France, Hong Kong, United States of America, Singapore,                 Sweden and Switzerland.

(ii)    Counterparty is not a Multibranch Party.

(xix)   Offices. Section 10(a) of the ISDA Form shall apply with respect to UBS         AG.

(xx)    Payments on Early Termination. For the purpose of Section 6(e) of this         Agreement:

(i)     Market Quotation will apply.         (ii)    The Second Method will apply.

(xxi)   Event of Default relating to Bankruptcy. Clause (2) of Section 5(a)(vii)         shall not apply to Counterparty.

(xxii)  Affiliate will have the meaning specified in Section 14 of the ISDA         Form Master Agreement, provided that the Counterparty shall be deemed to         not have any Affiliates for purposes of this Agreement, including for         purposes of Section 6(b)(ii).

(xxiii) Compliance with Regulation AB.

(i) UBS AG agrees and acknowledges that Wells Fargo Asset Securities Corporation (the Depositor) is required under Regulation AB under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the Exchange Act) (Regulation AB), to disclose certain financial information regarding UBS AG, depending on the aggregate Significance Percentage (as defined in Item 1115 of Regulation AB) of all Transactions under this Agreement, together with any other transactions that fall within the meaning of derivative contracts for the purposes of Item 1115 of Regulation AB between UBS AG and Counterparty, as calculated from time to time in accordance with the Calculation Methodology (as defined below).

(ii) It shall be a swap disclosure event (Swap Disclosure Event) if, on any Business Day after the date hereof, the Depositor notifies UBS AG the Significance Percentage has reached one of the thresholds for significance of derivative contracts set forth in Item 1115 of Regulation AB (based on a reasonable determination by the Depositor, in good faith and using the Calculation Methodology, of such Significance Percentage).

(iii) Upon the occurrence of a Swap Disclosure Event, UBS AG, at its own expense, shall (a) provide to the Depositor the applicable Swap Financial Disclosure (as defined below), (b) secure another entity to replace UBS AG as party to this Agreement on terms substantially similar to this Agreement and subject to prior notification to the Swap Rating Agencies, which entity (or a guarantor therefor) meets or exceeds the Approved Rating Thresholds (or which satisfies the Rating Agency Condition) and which entity is able to provide the appropriate Swap Financial Disclosure or (c) obtain a guaranty of UBS AG's obligations under this Agreement from an affiliate of UBS AG that is able to comply with the financial information disclosure requirements of Item 1115 of Regulation AB, such that disclosure provided in respect of the affiliate will, in the judgment of counsel to the Depositor, satisfy any disclosure requirements applicable to the Swap Provider, cause such affiliate to provide Swap Financial Disclosure and cause such affiliate to provide indemnity for the Swap Financial Disclosure that is reasonably acceptable to the Depositor. If permitted by Regulation AB, any required Swap Financial Disclosure may be provided by reference to or incorporation by reference from reports filed pursuant to the Exchange Act.

(iv) UBS AG agrees that, in the event that UBS AG provides Swap Financial Disclosure to the Depositor in accordance with paragraph (iii)(a) above, or causes its affiliate to provide Swap Financial Disclosure to the Depositor in accordance with paragraph (iii)(c) above, it will indemnify and hold harmless the Depositor, its respective directors or officers and any person controlling the Depositor, from and against any and all losses, claims, damages and liabilities (any Damage) caused by any untrue statement or alleged untrue statement of a material fact contained in such Swap Financial Disclosure or caused by any omission or alleged omission to state in such Swap Financial Disclosure a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however that the foregoing shall not apply to any Damage caused by the negligence or any willful action of the Depositor or any other party (other than UBS AG or any of its affiliates or any of their respective agents), including without limitation any failure to calculate the Significance Percentage according to the terms of this Agreement or to make any





filing as and when required under Regulation AB.

(v) In the event that UBS AG provides the information referred to above, such information shall be provided not later than five (5) business days prior to the date in which the Master Servicer is required to file a Form 10-D for such Distribution Date.

For the purposes hereof:

Calculation Methodology means such method for determining maximum probable exposure of a derivative contract as reasonably determined by the Depositor.

Swap Financial Disclosure means the financial information specified in Item   1115 of Regulation AB relating to the applicable Significance Percentage and   any necessary auditors consents relating to such financial information.

Additional Termination Events:

The following Additional Termination Events will apply to UBS AG:

1. Ratings Event. If a Ratings Event (as defined below) has occurred and UBS AG has not complied with the requirements set forth in the succeeding paragraph within the 30 day time period specified therein, then an Additional Termination Event shall have occurred with respect to UBS AG and UBS AG shall be the sole Affected Party with respect to such an Additional Termination Event.

Rating Agency Downgrade:

If a Ratings Event occurs with respect to UBS AG, then UBS AG shall, at       its own expense, (i) assign this Transaction hereunder to a third party       within thirty (30) days of such Ratings Event that meets or exceeds, or as       to which any applicable credit support provider meets or exceeds, the       Approved Rating Threshold (as defined below) on terms substantially       similar to this Confirmation or (ii) deliver collateral acceptable in a       form and amount acceptable to Fitch Ratings (Fitch) and Moody's       Investors Service Inc. (Moody's) within thirty (30) days of such Ratings       Event and subject to written confirmation from Fitch and Moody's that       delivery of such collateral in the context of such downgrade will not       result in a withdrawal, qualification or downgrade of the then current       ratings assigned to the Certificates. For the avoidance of doubt, a       downgrade of the rating on Wells Fargo Mortgage Backed Securities 2006-6       Trust, Mortgage Pass-Through Certificates, Series 2006-6, Class I-A-22       (the Certificates) could occur in the event that UBS AG does not post       sufficient collateral.

For purposes of this Transaction, a Ratings Event shall occur with       respect to UBS AG if its long term unsecured debt rating (the Long Term       Rating) ceases to be rated at least A1 by Moody's Investors Service,       Inc. or at least A+ by Fitch Ratings (such ratings being referred to as       the Approved Ratings Threshold), (unless, within 30 days after such       withdrawal or downgrade Fitch and Moody's have reconfirmed the rating of       the Certificates which were in effect immediately prior to such withdrawal       or downgrade).

2. Swap Disclosure Event. If upon the occurrence of a Swap Disclosure Event (as defined in paragraph (xxiii) above), UBS AG has not, within 5 business days after such Swap Disclosure Event complied with any of the provisions set forth in paragraph (xxiii) above, then an Additional Termination Event shall have occurred with respect to UBS AG with UBS AG as the sole Affected Party with respect to such Additional Termination Event.

Transfer, Amendment and Assignment:

No transfer, amendment, waiver, supplement, assignment or other modification of this Transaction (other than the pledge of this Transaction to the Master Servicer pursuant to the Pooling and Servicing Agreement) shall be permitted by either party unless Moody's and Fitch have been provided notice of the same and confirm in writing (including by facsimile transmission) that they will not downgrade, qualify, withdraw or otherwise modify its then-current rating of the Certificates; provided however that except with respect to a transfer at the direction of UBS, nothing in this provision shall impose any obligation on UBS to give notice to any rating agency.

Permitted Security Interest:

For purposes of Section 7 of the Agreement, UBS AG hereby consents to the Permitted Security Interest.

Permitted Security Interest means the collateral assignment by the Counterparty of the Cap Collateral to the Master Servicer pursuant to the Pooling and Servicing Agreement, and the granting to the Master Servicer of a security interest in the Cap Collateral pursuant to the Pooling and Servicing Agreement.

Cap Collateral means all right, title and interest of the Counterparty in this Agreement, each Transaction hereunder, and all present and future amounts payable by UBS AG to the Counterparty under or in connection with the Agreement or any Transaction governed by the Agreement, whether or not evidenced by a Confirmation, including, without limitation, any transfer or termination of any such Transaction.

Payer Tax Representations

For the purposes of Section 3(e) of the Master Agreement, UBS AG will make the





following representation and Counterparty will not make the following representation: it is not required by any applicable law, as modified by the practice of any relevant governmental revenue authority, of any Relevant Jurisdiction to make any deduction or withholding for or on account of any Tax from any payment (other than interest under Section 2(e), 6(d)(ii) or 6(e) of the Master Agreement) to be made by it to the other party under this Agreement. In making this representation, it may rely on (i) the accuracy of any representations made by the other party pursuant to Section 3(f) of the Master Agreement, (ii) the satisfaction of the agreement contained in Section 4(a)(i) or 4(a)(iii) of the Master Agreement and the accuracy and effectiveness of any document provided by the other party pursuant to Section 4(a)(i) or 4(a)(iii) of this Agreement and (iii) the satisfaction of the agreement of the other party contained in Section 4(d) of this Agreement, provided that it shall not be a breach of this representation where reliance is placed on clause (ii) and the other party does not deliver a form or document under Section 4(a)(iii) of this Agreement by reason of material prejudice to its legal or commercial position.

Payee Tax Representations

For the purpose of Section 3(f) of the ISDA Form, UBS AG makes the following representation:

It is a non-U.S. branch of a foreign person as that term is used in section 1.1441-4(a)(3)(ii) of the United States Treasury Regulations (the Regulations) for United States federal income tax purposes.

For the purpose of Section 3(f) of the ISDA Form, the Counterparty makes the following representations:

1.    The Counterparty is a New York common law trust and is regarded as a          Real Estate Mortgage Investment Conduit for federal income tax          purposes.

2.    It is a U.S. person (as that term is used in section          1.1441-4(a)(3)(ii) of the United States Treasury Regulations for United          States federal income tax purposes.

Agreement to Deliver Documents

For purposes of Section 4(a)(i) and (ii) of the ISDA Form, the parties agree to deliver the following documents as applicable.

Party required       Form/Document/            Date by which to deliver           Certificate               to be delivered document

UBS AG and           Any form or document      Promptly upon Counterparty         required or reasonably    reasonable                      requested to allow the    demand by the                      other party to make       other party.                      payments without any                      deduction or                      withholding for or on                      account of any Tax, or                      with such deduction or                      withholding at a                      reduced rate. Counterparty         One duly executed and     Promptly upon                      completed U.S. Internal   reasonable                      Revenue Service Form      demand by the                      W-9 (or successor         other party                      thereto)

Party required to  Form/Document/             Date by which to  Covered by Section deliver document   Certificate                be delivered      3(d) Representation                                                         UBS AG             Any documents required     Upon the          Yes                    by the receiving party     execution and                    to evidence the            delivery of                    authority of the           this Agreement                    delivering party for it    and such                    to execute and deliver     Confirmation                    this Confirmation and to                    evidence the authority                    of the delivering party                    to perform its                    obligations under this                    Agreement or the                    Transaction governed by                    this Confirmation

UBS AG             A certificate of an        Upon the          Yes                    authorized officer of the  execution and                    party, as to the           delivery of                    incumbency and authority   this                    of the respective          Confirmation                    officers of the party                    signing this Confirmation

UBS AG             Opinion of Counsel for     No later than     No                    UBS AG                     15 days after





closing

Relationship Between Parties Each party will be deemed to represent to the other party on the date on which it enters into this Transaction that (in the absence of a written agreement between the parties which expressly imposes affirmative obligations to the contrary for this Transaction):

(a) Non-Reliance. Each party is acting for its own account, and has made its own independent decisions to enter into this Transaction and this Transaction is appropriate or proper for it based upon its own judgment and upon advice from such advisers as it has deemed necessary. Each party is not relying on any communication (written or oral) of the other party as investment advice or as a recommendation to enter into this Transaction; it being understood that information and explanation relating to the terms and conditions of this Transaction shall not be considered investment advice or a recommendation to enter into this Transaction. No communication (written or oral) received from the other party shall be deemed to be an assurance or guarantee as to the expected results of this Transaction.

(b) Assessment and Understanding. Each party is capable of assessing the merits of and understands (on its own behalf or through independent professional advice), and accepts, the terms, conditions and risks of this Transaction. Each party is also capable of assuming and assumes, the risks of this Transaction.

(c) Status of the Parties. Neither party is acting as a fiduciary for or as an adviser to the other in respect of this Transaction.

(d) Eligible Contract Participant. Each party constitutes an eligible contract participant as such term is defined in Section 1(a)12 of the Commodity Exchange Act, as amended.

Master Servicer Capacity. It is expressly understood and agreed by the parties hereto that insofar as this Confirmation is executed by the Master Servicer (i) this Confirmation is executed and delivered by Wells Fargo Bank, N.A., not in its individual capacity, but solely as Master Servicer with respect to Wells Fargo Mortgage Backed Securities 2006-6 Trust (the Trust) under the Pooling and Servicing Agreement, dated as of April 27, 2006 (the Pooling and Servicing Agreement) in the exercise of the powers and authority conferred upon and vested in it thereunder and pursuant to instruction set forth therein, (ii) each of the representations, undertakings and agreements herein made on the part of the Trust is made and intended not as a personal representation, undertaking or agreement by Wells Fargo Bank, N.A., but is made and intended for the purpose of binding only the Trust, (iii) nothing herein contained shall be construed as imposing any liability on Wells Fargo Bank, N.A. individually or personally, to perform any covenant either express or implied contained herein, all such liability, if any, being expressly waived by the parties hereto and by any Person claiming by, through or under the parties hereto, and (iv) under no circumstances shall Wells Fargo Bank, N.A. in its individual capacity be personally liable for the payment of any indebtedness or expenses or be personally liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Trust under this Confirmation or any other related documents (other than the Master Servicer's express obligations under the Pooling and Servicing Agreement).

References in this clause to a party shall, in the case of UBS AG and where the context so allows, include references to any affiliate of UBS AG.

Account Details for UBS AG: Currency:                USD Correspondent Bank:      UBS AG, STAMFORD BRANCH Swift Address:           UBSWUS33XXX Favour:                  UBS AG LONDON BRANCH Swift Address:           UBSWGB2LXXX Account No:              101-wa-140007-000

Offices (a) The office of UBS AG for the Interest Rate Cap Transaction is London; and The office of Counterparty for the Interest Rate Cap Transaction is:

9062 Annapolis Road Columbia, Maryland 21045 Attn: Client Manager - WFMBS 2006-6 Telephone: 410.884.2000 Fax: 410.715.2380

Contact Names at UBS AG: Payment Inquiries        Elisa Doctor                Email:                                       &bbsp;              DL-USOTCRATES-SETTS@ubs.com

Phone: 203.719.1110 Pre Value Payments:      Pre Value Payment           203.719.1110                          Investigations: Post Value Payments:     Post Value Payment          203.719.1110                          Investigations: Confirmation Queries:    Confirmation Control:       203.719.3373 ISDA Documentation:      Credit Risk Management:     212.713.1170 Swift:                   UBSWGB2L Fax:                     203.719.0274 Address:                 UBS AG





100 Liverpool Street                          London EC2M 2RH

Address for notices or communications to the Counterparty:

9062 Old Annapolis Road Columbia, MD 21045 Attn: Corporate Trust Services - WFMBS 2006-6

Payments to Counterparty: Wells Fargo Bank, NA San Francisco, CA ABA #: 121-000-248 Acct #: 3970771416 Acct Name: SAS Clearing For Further Credit: Interest Rate Cap, Account # 50915701

(For all purposes)

Please confirm that the foregoing correctly sets forth the terms and conditions of our agreement by executing a copy of this Confirmation and returning it to us or by sending to us a letter or facsimile substantially similar to this letter, which letter or facsimile sets forth the material terms of the Transaction to which this Confirmation relates and indicates your agreement to those terms or by sending to us a return letter or facsimile in the form attached.

This Confirmation may be executed in several counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

Yours Faithfully For and on Behalf of UBS AG, London Branch

By: /s/ Todd Harper                  By: /s/ Mark J. Evans II

Name :  Todd Harper                  Name  : Mark J. Evans II Title : Associate Director           Title:  Director         UBS Operations                       Operations

Acknowledged and Agreed by Wells Fargo Bank N.A., not individually, but solely as Master Servicer on behalf of Wells Fargo Mortgage Backed Securities 2006-6 Trust By: /s/ Jennifer L. Richardson

Name :   Jennifer L. Richardson Title :  Assistant Vice President

UBS AG London Branch, 1 Finsbury Avenue, London, EC2M 2PP UBS AG is a member of the London Stock Exchange and is regulated in the UK by the Financial Services Authority.  Representatives of UBS Limited introduce trades to UBS AG via UBS Limited. 
Question: Highlight the parts (if any) of this contract related to Cap On Liability that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.

Ex Output:
12185


Ex Input:
Exhibit 4.36

                              DEVELOPMENT AGREEMENT

                                     between

LEO PHARMA A/S of Industriparken 55, DK-2750 Ballerup, Denmark (hereinafter referred to as LEO) ---

                                       and

GALEN (CHEMICALS) LIMITED of 4 Adelaide Street, Dun Laoghaire, Co. Dublin, Ireland (hereinafter referred to as GALEN).

Capitalized terms not otherwise defined herein shall have the meanings set forth in Article I of this Agreement.

WHEREAS Bristol-Myers Squibb Company (BMS) has entered into a co-promotion agreement with GALEN regarding Dovonex(R) Product in the Territory (the Co-promotion Agreement).

WHEREAS GALEN and BMS have entered into an option agreement (the Option Agreement) in which GALEN has options to acquire all of BMS's rights and to assume BMS's obligations (the Option) under the agreement dated September 28, 1989 between BMS (as successor to E.R. Squibb & Sons Inc.) and LEO, as amended July 6, 1992 and April 8, 1993 and as of the date hereof and the Product Supply Agreement between Bristol-Myers Squibb Company and LEO dated as of April 8, 1993 (each as may be amended or supplemented by the parties in the future, collectively, the BMS Agreements); and

WHEREAS BMS has given up its rights under the BMS Agreements to a pharmaceutical preparation containing both the Compound and Betamethasone Dipropionate in an ointment (the Combination Product) as of the date hereof; and

WHEREAS LEO has developed and owns proprietary information regarding the Combination Product, and has filed a patent application for the Combination Product; and

WHEREAS GALEN has marketing expertise within the dermatological field; and

WHEREAS LEO and GALEN have entered into a License and Supply Agreement dated as of even date herewith between LEO and GALEN regarding the Combination Product (the Dovobet(R) Agreement) and subject to the coming into force of that Agreement under its terms, LEO has appointed GALEN as its exclusive distributor in the Territory of the Combination Product expected to be marketed under the trademark Dovobet(R); and

WHEREAS GALEN and LEO have entered into a License and Supply Agreement dated as of even date herewith pursuant to which GALEN will be the exclusive distributor of Dovonex(R) Product in the Territory subsequent to the exercise of the Option by GALEN and the acquisition of BMS's rights and assumption of BMS's obligations under the BMS Agreements by GALEN (the Dovonex(R) Agreement); and

WHEREAS GALEN, if the FDA mandates an additional pivotal phase III clinical trial for the Combination Product, will financially support LEO;

NOW THEREFORE the Parties hereby agree as follows:

I - DEFINITIONS

1.1      AB rated means, with respect to any Product (as defined in the          Dovonex(R) Agreement), a pharmaceutical product which is an AB-rated          equivalent to the Product, as defined in the 22nd edition of Approved          Drug Products with Therapeutic Equivalence Evaluations issued by the          United States Department of Health and Human Services.

1.2      Action or Proceeding means any action, suit, proceeding, arbitration          or Governmental or Regulatory Authority action, notification,          investigation or audit.

1.3      Affiliate means, with respect to any Person, any Person which,          directly or indirectly, controls, is controlled by, or is under common          control with, the specified Person. For purposes of this definition,          the term control as applied to any Person, means the possession,          directly or indirectly, of at least fifty-one per cent (51%) of the          power to direct or cause the direction of the management of that          Person, whether&sbsp;through ownership of voting securities or otherwise.

1.4      Agreement means this Development Agreement between LEO and GALEN.

1.5      Compound means the compound Calcipotriene, a vitamin D analogue with          the formula C27H4003.

                                                                               2

1.6      Dovonex(R) Product means the Compound marketed in the Territory under          the trademark Dovonex(R).

1.7      FDA means the United States Food and Drug Administration.

1.8      GALEN Information means any information (including, but not limited          to, technical improvements, financial and marketing information)          developed, made and/or generated by GALEN relating to and made as a





         result of its work with the Combination Product.

1.9      Governmental or Regulatory Authority means any court, tribunal,          arbitrator, agency, commission, official or other instrumentality of          the United States or any relevant country, state, province, county,          city or other political subdivision.

1.10     IND means the Investigational New Drug Application, as defined by the          United States Federal Food, Drug and Cosmetic Act and applicable          regulations promulgated thereunder as amended from time to time, filed          in the United States, for the Combination Product.

1.11     Laws means all laws, statutes, rules, regulations, ordinances and          other pronouncements having the effect of law of any relevant          Governmental or Regulatory Authority.

1.12     LEO Logo Guidelines means the guidelines for use of the LEO name and          the Assyrian Lion logo attached to the Dovobet(R) Agreement.

1.13     LEO Product Branding means the Trademark, the LEO name, the Assyrian          Lion, the LEO Logo Guidelines, the LEO Product Concept and any domain          names or websites related to the Combination Product in the Territory.

1.14     LEO Product Concept means the global design concept for packaging and          promotional materials related to the Combination Product developed by          LEO.

1.15     Losses means any and all damages, fines, fees, penalties,          deficiencies, losses and expenses (including without limitation          interest, court costs, reasonable fees of attorneys, accountants and          other experts or other expenses of litigation or other proceedings or          of any claim, default or assessment).

1.16     Master Agreement means the Master Agreement dated as of even date          herewith between LEO and GALEN.

1.17     NDA means a New Drug Application filed with the FDA for the          Combination Product, requesting permission to place a drug on the          market in accordance with 21 C.F.R. Part 314 and all supplements filed          pursuant to the requirements of the FDA, including all documents, data          and other

                                                                               3

         information concerning the Combination Product which are necessary for          FDA approval to market a product in the United States.

1.18     Party means GALEN or LEO, as the case may be, and Parties means          GALEN and LEO.

1.19     Person means any individual, firm, corporation, partnership, limited          liability company, trust, joint venture, Governmental or Regulatory          Authority or other entity or organization.

1.20     Technical Information means all information in the possession of LEO          and/or its Affiliates, and any information transferred from BMS to          GALEN, regarding preclinical, chemical-pharmaceutical and clinical data          or other scientific information (including specifications, master batch          records, analytical methods including validation protocol and the drug          master file), or secret know-how about the Combination Product          including, but not limited to marketing know-how and show-how or uses          for the Combination Product in the possession of LEO regarding the          Combination Product necessary for GALEN to fulfil its obligations under          the Agreement.

1.21     Territory means the fifty (50) states of the United States of          America, the District of Columbia, its territories and current          possessions.

1.22     Trademark means the trademark Dovobet(R) or any other trademark LEO          may select for the Combination Product.

II - WORK BY LEO

2.1      LEO has performed any and all preclinical, clinical and other studies          necessary to obtain marketing approval for the Combination Product in          Europe and has borne all costs and expenses associated therewith.          Furthermore, LEO will perform any and all additional studies, required          specifically by the FDA and will bear all costs and expenses associated          therewith except for the obligation of GALEN described in Article 3.1.

         A development plan is attached as Appendix I

2.2      LEO is responsible for obtaining approval of the NDA in the United          States.

III - OBLIGATIONS OF GALEN

3.1    If the FDA mandates that a second pivotal phase III clinical trial for        the Combination Product is required for registration in the United        States, GALEN agrees to pay 50% of the reasonable costs for

                                                                               4





         said study, such costs to be invoiced by LEO on a quarterly basis. The          payments are non-refundable.

3.2      GALEN will provide reasonable assistance to LEO in its endeavours to          obtain approval of the NDA in the United States.

3.3      Within thirty (30) days after the date hereof, GALEN will pay to LEO          US$5,000,000 (five million United States dollars) to reimburse LEO for          a portion of the actual development costs that have been incurred by          LEO. This payment is non-refundable.

IV - INDEMNIFICATION

4.1      LEO shall indemnify and hold GALEN and its agents, directors, officers          and employees and representatives harmless from and against any and all          Losses which they may at any time incur by reason of any Action or          Proceeding brought by any Governmental or Regulatory Authority or other          third party against GALEN arising out of or resulting from (a) any          misrepresentation, breach of warranty or non-fulfilment of or failure          to perform any agreement or covenant made by LEO in this Agreement, (b)          the use of the Combination Product in any clinical trial, or (c) any          other negligent act or omission of LEO.

4.2      GALEN shall indemnify and hold LEO and its agents, directors, officers          and employees and representatives harmless from and against any and all          Losses which they may at any time incur by reason of any Action or          Proceeding brought by any Governmental or Regulatory Authority or other          third party against LEO arising out of or resulting from (a) any          misrepresentation, breach of warranty or non-fulfilment of or failure          to perform any agreement or covenant made by GALEN in this Agreement,          or (b) any other negligent act or omission of GALEN.

4.3      The obligation of the Parties in this Article IV shall survive the          expiration or earlier termination of this Agreement to the extent          permitted by applicable Law.

4.4      In any case under this Article IV, where GALEN or LEO is to indemnify          the other, the control of the defence of any Action or Proceeding and          negotiations for settlement and compromise thereof, shall repose with          the indemnifying Party, except that nothing in this paragraph shall be          construed to relieve either Party hereto of the obligation to give the          other all reasonable co-operation, assistance and authority necessary          to permit full and complete defence of any Action or Proceeding;          provided, however, that no Party will settle any of such claims without          consent of the other Party; however, such consent shall not be          unreasonably withheld. Both Parties shall, if desired, be allowed to          participate, at their own expense, directly or through a representative          e.g. their product liability insurers, in any Action or Proceeding.

                                                                               5

V - CONFIDENTIALITY

5.1      All Technical Information disclosed to GALEN and all GALEN Information          disclosed to LEO shall be considered confidential regardless of          designation, and shall not be disclosed by the receiving Party to any          third party or used outside the scope of this Agreement without the          prior written consent of the disclosing Party except to a duly          authorised Governmental or Regulatory Authority in connection with the          registration or regulation of the Combination Product or if otherwise          required by Law. In the event that a Party is asked to disclose any          confidential information to a Governmental or Regulatory Authority,          such Party will - if possible - notify the nondisclosing Party          sufficiently prior to making such disclosure so as to allow the          nondisclosing Party adequate time to take whatever action it may deem          to be appropriate to protect the confidentiality of the information.          The obligation not to disclose Technical Information and GALEN          Information shall not apply to (a) any information that it now or later          becomes publicly available through no fault of the receiver, its          officers, employees or agents; (b) any information that the receiver          obtains from a third party not under a confidentiality obligation to          the discloser with respect to such information; (c) any information          that the receiver already has in its possession as indicated in its          written records; and (d) any information that is independently          developed or created by the receiver.

5.2      Each Party shall keep the terms of this Agreement confidential and          shall not disclose the same&bbsp;to any third party other than (i) by          agreement of the Parties hereto, or (ii) as required by Law or stock          exchange regulation or an order of a competent Governmental or          Regulatory Authority; provided that prior to disclosure pursuant to          (ii) above, the disclosing Party shall - if possible - notify the          nondisclosing Party sufficiently prior to making such disclosure so as          to allow the nondisclosing Party adequate time to take whatever action          it may deem to be appropriate to protect the confidentiality of the          information.

5.3      Neither Party shall make any press release or other public announcement          or other disclosure to third Parties relating to this Agreement without          the prior consent of the other Party, which consent shall not be          unreasonably withheld, except where required by applicable Law;          provided that prior to disclosure, the disclosing Party shall notify          the nondisclosing Party sufficiently prior to making such disclosure so          as to allow the nondisclosing Party adequate time to take whatever          action it may deem to be appropriate to protect the confidentiality of          the information.





5.4      This Article V shall survive the termination of this Agreement for a          period of ten (10) years, provided, however, that following the          termination of this Agreement LEO shall be free to use all data,          information or other confidential information relating to the          Combination Product and following termination of this Agreement, GALEN          shall be free to use all GALEN Information.

                                                                               6

VI - COMPLIANCE WITH LAWS

Both LEO and GALEN shall observe all applicable Laws in effect in fulfilling their obligations under this Agreement.

VII - TERM AND TERMINATION - CONSEQUENCES OF TERMINATION

7.1      This Agreement will be effective when signed by both Parties provided          that the Co-promotion Agreement and the Option Agreement have been          signed and have come into force and provided also that said agreements          do not prohibit GALEN from entering into the Dovonex(R) Agreement and          the Dovobet(R) Agreement.

7.2      This Agreement shall terminate if (a) the Dovonex(R) Agreement is          terminated by LEO pursuant to Articles 15.4, 15.7 or 15.8 thereof or          (b) the Dovonex(R) Agreement is terminated by LEO pursuant to Article          15.2 thereof in the event that GALEN has not exercised the Option for          reasons not including that (i) the aggregate turnover of the Products          in the U.S. during the period 1 July 2004 - 30 June 2005, as measured          by IMSHealth, is equal to or less than US$50,000,000 (fifty million          dollars) or (ii) on or prior to August 1, 2005 a generic product that          is AB rated to any Product (as defined in the Dovonex(R) Agreement) is          approved by the FDA and has become commercially available, provided,          for purposes of this subclause (ii), that GALEN has not provided          assistance to the holder of the registration for the AB rated product          to obtain such registration, or (c) the Dovobet(R) Agreement comes into          force and GALEN has fulfilled its obligations under this Agreement,          unless prior terminated in accordance with any of the provisions          hereof.

7.3      In the event that one of the Parties hereto materially defaults or          breaches any of the provisions of this Agreement, the other Party shall          have the right to terminate this Agreement upon sixty (60) days'          written notice, provided, however, that if the Party in default, within          the sixty day period referred to, remedies the said default or breach,          the Agreement shall continue in full force and effect.

7.4      In the event of termination of this Agreement under the provisions of          this Article VII GALEN shall not be relieved of the duty and          obligations to pay in full, any payments due and unpaid at the          effective date of such termination. In such event GALEN shall:

         (a)      return any and all Technical Information and any other                   information relating to the Combination Product provided to                   GALEN and shall make no further use thereof;

         (b)      cease to make use of the Trademark, the other LEO Product                   Branding and all other information related to the Combination                   Product, and all rights in the Trademark, the other

                                                                               7

                  LEO Product Branding and all other information relating to the                   Combination Product will promptly revert to LEO and be                   transferred to LEO;

         (c)      if GALEN is then the owner of any patents specifically related                   to the Combination Product, GALEN shall transfer such                   ownership to LEO, except for LEO being in breach in which case                   GALEN will sell said patents and LEO will purchase said                   patents at a price equal to the expenses GALEN has borne in                   relation to developing, establishing and maintaining said                   patent rights;

         (d)      if GALEN is then the owner of any patents, which in part                   relates to the Combination Product then LEO, its Affiliates                   and partners shall have a royalty free license to such patents                   for the term of the patents;

         (e)      if GALEN is then the owner of any data related to the                   Combination Product, including, but not limited to, any data                   related to any study performed under this Agreement such data                   shall be transferred to LEO. At such time, LEO shall have the                   right, but not the obligation, to have assigned to LEO any                   third party clinical agreement then pending;

         (f)      GALEN shall transfer the NDA, the IND and any other relevant                   registrations related to the Combination Product held by                   GALEN, if any, to LEO or its designee.

         In the event that LEO terminates this Agreement pursuant to Article 7.3          or Article 7.2(a) or (b), the transfers required under Article 7.4 (a),          (b), (c), (e) and (f) shall be made free of charge to LEO. Otherwise,          the costs of transfers shall be split evenly between the parties.

VIII - ASSIGNABILITY





This Agreement shall be binding upon, and shall inure to the benefit of successors of the Parties hereto, or to any assignee of all of the goodwill and entire business assets of a Party hereto relating to pharmaceuticals, but shall not otherwise be assignable without the prior written consent of the other Party.

For the avoidance of doubt, LEO agrees and acknowledges that GALEN may perform any or all of its obligations under this agreement through its U.S. Affiliates, Warner Chilcott, Inc..

IX - AMENDMENT OF AGREEMENT; WAIVER; SEVERABILITY

9.1      This Agreement shall not be changed or modified orally.

9.2      Any term or condition of this Agreement may be waived at any time by          the Party that is entitled to the benefit thereof, but no such waiver          shall be effective unless set forth in a written instrument

                                                                               8

         duly executed by or on behalf of the Party waiving such term or          condition. No waiver by either Party of any term or condition of this          Agreement, in any one or more instances, shall be deemed to be or          construed as a waiver of the same or any other term or condition of          this Agreement on any future occasion. All remedies, either under this          Agreement or by Law or otherwise afforded, will be cumulative and not          alternative.

9.3      If any provision of this Agreement is held to be illegal, invalid or          unenforceable under any applicable present or future Law, and if the          rights or obligations of any Party hereto under this Agreement will not          be materially and adversely affected thereby, (a) such provision will          be fully severable, (b) this Agreement will be construed and enforced          as if such illegal, invalid or unenforceable provision had never          comprised a part hereof, (c) the remaining provisions of this Agreement          will remain in full force and effect and will not be affected by the          illegal, invalid or unenforceable provision or by its severance          herefrom and (d) in lieu of such illegal, invalid or unenforceable          provision, the Parties will add as a part of this Agreement, a legal,          valid and enforceable provision as similar in terms to such illegal,          invalid or unenforceable provision as may be possible.

X - STATUS OF PRIOR AGREEMENTS

This Agreement together with the Master Agreement, the Dovonex(R) Agreement and the Dovobet(R) Agreement constitute the entire agreement between the Parties hereto with respect to the subject matter and supersede all previous agreements, whether written or oral.

XI - FORCE MAJEURE

The occurrence of an event which materially interferes with the ability of a Party to perform its obligations or duties hereunder which is not within the reasonable control of the Party affected, not due to malfeasance, and which could not with the exercise of due diligence have been avoided (Force Majeure) including, but not limited to, fire, accident, labour difficulty, strike, riot, civil commotion, act of God, delay or errors by shipping companies or change in Law shall not excuse such Party from the performance of its obligations or duties under this Agreement, but shall merely suspend such performance during the continuation of Force Majeure. The Party prevented from performing its obligations or duties because of Force Majeure shall promptly notify the other Party hereto (the Other Party) of the occurrence and particulars of such Force Majeure and shall provide the Other Party, from time to time, with its best estimate of the duration of such Force Majeure and with notice of the termination thereof. The Party so affected shall use its best efforts to avoid or remove such causes of non-performance. Upon termination of Force Majeure, the performance of any suspended obligation or duty shall promptly recommence. Neither Party shall be liable to the Other Party for any direct, indirect, consequential, incidental, special, punitive or exemplary damages arising out of or relating to the

                                                                               9

suspension or termination of any of its obligations or duties under this Agreement by reason of the occurrence of Force Majeure. In the event that Force Majeure has occurred and is continuing for a period of at least six (6) months, the Other Party shall have the right to terminate this Agreement upon thirty (30) days' notice.

XII - PARTNERSHIP/AGENCY; THIRD PARTIES

12.1     None of the provisions of this Agreement shall be deemed to constitute          the relationship of partnership or agency between the Parties, and          neither Party shall have any authority to bind the other Party in any          way except as provided in this Agreement.

12.2     The Parties agree that no third party which is not a Party to this          Agreement is intended to benefit from or shall have any right to          enforce any provision of this Agreement.

XIII - GOVERNING LAW

THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE, WITHOUT REGARD TO THE CONFLICTS OF LAW PRINCIPLES OF SUCH STATE OTHER THAN SECTIONS 5-1401 OF THE NEW YORK GENERAL





OBLIGATIONS LAW.

Each Party irrevocably submits to the exclusive jurisdiction of (a) the Supreme Court of the State of New York, New York County, and (b) the United States District Court for the Southern District of New York, for the purposes of any suit, action or other proceeding arising out of this Agreement or any transaction contemplated hereby or thereby. Each Party agrees to commence any such action, suit or proceeding either in the United States District Court for the Southern District of New York or if such suit, action or other proceeding may not be brought in such court for jurisdictional reasons, in the Supreme Court of the State of New York, New York County. Each Party further agrees that service of any process, summons, notice or document by registered mail to such Party's respective address set forth above shall be effective service of process for any action, suit or proceeding in New York with respect to any matters to which it has submitted to jurisdiction in this Article XIII. Each Party irrevocably and unconditionally waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the transactions contemplated hereby and thereby in (i) the Supreme Court of the State of New York, New York County or (ii) the United States District Court for the Southern District of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.

                                                                              10

Each Party hereto hereby waives to the fullest extent permitted by applicable Law, any right it may have to a trial by jury in respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement.

XIV - NOTICES

Any notice hereunder shall be deemed to be sufficiently given if sent by registered mail or by fax followed by mail to:

In the case of GALEN:

                GALEN (CHEMICALS) LIMITED                 4 Adelaide Street                 Dun Laoghaire, Co. Dublin                 Ireland

                Fax: + 353 1 214 8477

With a copy to:

                Galen Holdings PLC                 Att. Chief Executive Officer                 100 Enterprise Drive, Suite 280                 Rockaway, New Jersey 07866                 USA

                Fax: + 1 973 442 3362

In the case of LEO:

                LEO PHARMA A/S

                Att. CEO, President                 Industriparken 55                 DK-2750 Ballerup                 Denmark

                Fax: + 45 44 64 15 80

or such other address as the receiver shall have last furnished to the sender.

                                                                              11

IN WITNESS WHEREOF the Parties hereto have caused this Agreement to be duly executed in duplicate by their authorised officers as of the date last below written.

Rockaway, April ____, 2003                          Ballerup,  April ____, 2003

GALEN (CHEMICALS) LIMITED                           LEO Pharma A/S

------------------------------                      ---------------------------- Name:  Roger M. Boissonneault                       Name: Title:        Director                              Title: 
Question: Highlight the parts (if any) of this contract related to Cap On Liability that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.

Ex Output:
24842


Ex Input:
Schedule 13 G CUSIP No. 30734W208 EXHIBIT 1 JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on this Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: April 8, 2020 SCULPTOR CAPITAL LP

By: /s/ Thomas Sipp Thomas Sipp Chief Financial Officer SCULPTOR CAPITAL HOLDING CORPORATION

By: /s/ Thomas Sipp Thomas Sipp Chief Financial Officer SCULPTOR MANAGEMENT, INC.

By: /s/ Thomas Sipp Thomas Sipp Chief Financial Officer SCULPTOR MASTER FUND LTD

By: /s/ Thomas Sipp Thomas Sipp Chief Financial Officer 
Question: Highlight the parts (if any) of this contract related to Agreement Date that should be reviewed by a lawyer. Details: The date of the contract

Ex Output:

845